Immunogenicity and safety of quadrivalent inactivated influenza vaccine in children aged 6 to 35 months: A systematic review and meta-analysis

Hum Vaccin Immunother. 2023 Aug;19(2):2256510. doi: 10.1080/21645515.2023.2256510. Epub 2023 Oct 4.

Abstract

Evidence of the immunogenicity and safety of quadrivalent inactivated influenza vaccine in children aged 6 to 35 months has been emerging. To evaluate the immunogenicity and safety of quadrivalent inactivated influenza vaccine in children aged 6 to 35 months in a systematic review and meta-analysis. This meta-analysis included 12 studies with 6722 participants receiving QIV, 3575 participants receiving TIV, 4249 participants receiving full-dose QIV (F-QIV), and 3722 participants receiving half-dose QIV (H-QIV). Among children aged 6 to 35 months, QIV produces a better Immunogenicity against influenza B vaccine strains not contained in TIV. However, injection site reaction was more common for QIV, F-QIV showed superior efficacy for the B lineage, but fever and injection site pain was more frequently reported for F-QIV than H-QIV. These data support the immunogenicity and safety of quadrivalent inactivated influenza vaccine among children aged 6 to 35 months.

Keywords: Random clinical trials; children aged 6 to 35 months; immunogenicity; influenza vaccine; safety; systematic review.

Publication types

  • Meta-Analysis
  • Systematic Review
  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Viral
  • Child
  • Hemagglutination Inhibition Tests
  • Humans
  • Immunogenicity, Vaccine
  • Influenza B virus
  • Influenza Vaccines*
  • Influenza, Human* / prevention & control
  • Injection Site Reaction
  • Vaccines, Combined
  • Vaccines, Inactivated

Substances

  • Influenza Vaccines
  • Antibodies, Viral
  • Vaccines, Inactivated
  • Vaccines, Combined

Grants and funding

This work was supported by the National Natural Science Foundation of the post-subsidy project in 2019 [grant Mr. Lei].